Pregnancy in Women With Vascular Malformations Carries High Risks of Postpartum Hemorrhage and Symptom Worsening, While Thromboembolism Clusters in Extensive Lower-Extremity Disease
Posted innews OB/GYN & Women’s Health Public Health

Pregnancy in Women With Vascular Malformations Carries High Risks of Postpartum Hemorrhage and Symptom Worsening, While Thromboembolism Clusters in Extensive Lower-Extremity Disease

A nationwide Dutch study suggests pregnancy in women with peripheral vascular malformations is frequently complicated by symptom progression and postpartum hemorrhage, with venous thromboembolism concentrated in extensive lower-extremity malformations.
Gender‑Affirming Hormone Therapy and Acute Cardiovascular Events: Dutch Cohort Finds Lower MI but Higher VTE in Transgender Women, Elevated MI and Stroke Risk in Transgender Men
Posted inCardiology Diabetes & Endocrinology news

Gender‑Affirming Hormone Therapy and Acute Cardiovascular Events: Dutch Cohort Finds Lower MI but Higher VTE in Transgender Women, Elevated MI and Stroke Risk in Transgender Men

A large Dutch cohort study found that after adjusting for socioeconomic status and lifestyle, transgender women on oestradiol had lower myocardial infarction (MI) risk but higher venous thromboembolism (VTE) risk; transgender men on testosterone had higher MI and ischaemic stroke risk.
Rare but Real: Higher Risks of Vascular and Inflammatory Disease After SARS‑CoV‑2 Infection Than After BNT162b2 Vaccination in Children and Adolescents
Posted innews Pediatrics Public Health

Rare but Real: Higher Risks of Vascular and Inflammatory Disease After SARS‑CoV‑2 Infection Than After BNT162b2 Vaccination in Children and Adolescents

A nationwide English cohort study (n≈13.9M) found transient but significant increases in rare vascular and inflammatory events after first SARS‑CoV‑2 infection and a smaller, short-lived increase in myocarditis/pericarditis after first BNT162b2 vaccination—supporting vaccination to reduce greater risks from infection.
Continuing Anticoagulation After Unprovoked VTE Lowers Recurrence but Raises Bleeding — Real‑World Target Trial Emulation Shows Net Clinical Benefit
Posted inCardiology Internal Medicine news

Continuing Anticoagulation After Unprovoked VTE Lowers Recurrence but Raises Bleeding — Real‑World Target Trial Emulation Shows Net Clinical Benefit

A large target‑trial emulation of US claims data found continued oral anticoagulation after ≥90 days for unprovoked VTE markedly reduced recurrent VTE and mortality, increased major bleeding, but produced an overall net clinical benefit that persisted through several years of follow‑up.